Holger Fuchs

8-(3-(<i>R</i>)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes

Matthias Eckhardt, Elke Langkopf, Michael Mark et al. · Journal of Medicinal Chemistry · 2007 · 284 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

Tissue distribution of the novel DPP‐4 inhibitor BI 1356 is dominated by saturable binding to its target in rats

Holger Fuchs, Rudolf Binder, Andreas Greischel · Biopharmaceutics & Drug Disposition · 2009 · 93 citations

Medicine, Pharmacokinetics, Pharmacology +13

Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans

Holger Fuchs, Jean‐Paul Tillement, Andreas Greischel et al. · Journal of Pharmacy and Pharmacology · 2009 · 90 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy

Lyubov Chaykovska, Karoline von Websky, Jan Rahnenführer et al. · PLoS ONE · 2011 · 81 citations · Full text

Medicine, Nephrology, Pharmacology +11

Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates

Clemens Braun, Atsushi Sakamoto, Holger Fuchs et al. · Molecular Pharmaceutics · 2017 · 58 citations

Medicine, Biochemistry, Pharmacology +17